BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bucarey SA, Noriega J, Reyes P, Tapia C, Sáenz L, Zuñiga A, Tobar JA. The optimized capsid gene of porcine circovirus type 2 expressed in yeast forms virus-like particles and elicits antibody responses in mice fed with recombinant yeast extracts. Vaccine 2009;27:5781-90. [PMID: 19664739 DOI: 10.1016/j.vaccine.2009.07.061] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen P, Zhang L, Chang N, Shi P, Gao T, Zhang L, Huang J. Preparation of virus-like particles for porcine circovirus type 2 by YeastFab Assembly. Virus Genes 2018;54:246-55. [PMID: 29417333 DOI: 10.1007/s11262-018-1537-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 So KK, Chun J, Luong NN, Seo HW, Kim DH. Expression of an immunocomplex consisting of Fc fragment fused with a consensus dengue envelope domain III in Saccharomyces cerevisiae. Biotechnol Lett 2021;43:1895-904. [PMID: 34245387 DOI: 10.1007/s10529-021-03161-7] [Reference Citation Analysis]
3 Chen Z, Li C, Zhu Y, Wang B, Meng C, Liu G. Immunogenicity of virus-like particles containing modified goose parvovirus VP2 protein. Virus Res 2012;169:306-9. [PMID: 22940567 DOI: 10.1016/j.virusres.2012.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
4 Zhang Y, Wang Z, Zhan Y, Gong Q, Yu W, Deng Z, Wang A, Yang Y, Wang N. Generation of E. coli-derived virus-like particles of porcine circovirus type 2 and their use in an indirect IgG enzyme-linked immunosorbent assay. Arch Virol 2016;161:1485-91. [DOI: 10.1007/s00705-016-2816-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
5 Zheng G, Lu Q, Wang F, Jin Q, Teng M, Zhang N, Ren T, Ding P, Zhang G. Selection of affinity peptides for the purification potential of porcine circovirus type 2 (PCV2) Cap virus-like particles (VLPs). RSC Adv 2017;7:38911-4. [DOI: 10.1039/c7ra05790c] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Chen ML, Guo Q, Wang RZ, Xu J, Zhou CW, Ruan H, He GQ. Construction of the yeast whole-cell Rhizopus oryzae lipase biocatalyst with high activity. J Zhejiang Univ Sci B 2011;12:545-51. [PMID: 21726061 DOI: 10.1631/jzus.B1000258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Bucarey SA, Pujol M, Poblete J, Nuñez I, Tapia CV, Neira-Carrillo A, Martinez J, Bassa O. Chitosan microparticles loaded with yeast-derived PCV2 virus-like particles elicit antigen-specific cellular immune response in mice after oral administration. Virol J 2014;11:149. [PMID: 25141864 DOI: 10.1186/1743-422X-11-149] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Beach NM, Meng XJ. Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2). Virus Res 2012;164:33-42. [PMID: 22005075 DOI: 10.1016/j.virusres.2011.09.041] [Cited by in Crossref: 129] [Cited by in F6Publishing: 114] [Article Influence: 11.7] [Reference Citation Analysis]
9 Nainys J, Lasickiene R, Petraityte-Burneikiene R, Dabrisius J, Lelesius R, Sereika V, Zvirbliene A, Sasnauskas K, Gedvilaite A. Generation in yeast of recombinant virus-like particles of porcine circovirus type 2 capsid protein and their use for a serologic assay and development of monoclonal antibodies. BMC Biotechnol 2014;14:100. [PMID: 25487652 DOI: 10.1186/s12896-014-0100-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
10 He Q, Cao Z, Wang P, Lu Q, Zheng H, Sun J. Efficient application of a baculovirus-silkworm larvae expression system for obtaining porcine circovirus type 2 virus-like particles for a vaccine. Arch Virol 2020;165:2301-9. [PMID: 32757056 DOI: 10.1007/s00705-020-04754-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chen X, Chen J, Zhang Y, Zhu P, Deng Y, Liu Q. Secreted expression of truncated capsid protein from porcine circovirus type 2 in Pichia pastoris. Biotechnol Lett 2016;38:959-67. [PMID: 26994771 DOI: 10.1007/s10529-016-2076-5] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Jung BK, Kim HR, Jang H, Chang KS. Replacing the decoy epitope of PCV2 capsid protein with epitopes of GP3 and/or GP5 of PRRSV enhances the immunogenicity of bivalent vaccines in mice. J Virol Methods 2020;284:113928. [PMID: 32650038 DOI: 10.1016/j.jviromet.2020.113928] [Reference Citation Analysis]
13 Xi X, Mo X, Xiao Y, Yin B, Lv C, Wang Y, Sun Z, Yang Q, Yao Y, Xuan Y, Li X, Yuan YA, Tian K. Production of Escherichia coli-based virus-like particle vaccine against porcine circovirus type 2 challenge in piglets: Structure characterization and protective efficacy validation. Journal of Biotechnology 2016;223:8-12. [DOI: 10.1016/j.jbiotec.2016.02.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
14 Patterson R, Eley T, Browne C, Martineau HM, Werling D. Oral application of freeze-dried yeast particles expressing the PCV2b Cap protein on their surface induce protection to subsequent PCV2b challenge in vivo. Vaccine 2015;33:6199-205. [PMID: 26476879 DOI: 10.1016/j.vaccine.2015.10.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
15 Tu Y, Wang Y, Wang G, Wu J, Liu Y, Wang S, Jiang C, Cai X. High-level expression and immunogenicity of a porcine circovirus type 2 capsid protein through codon optimization in Pichia pastoris. Appl Microbiol Biotechnol 2013;97:2867-75. [DOI: 10.1007/s00253-012-4540-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
16 Duan J, Yang D, Chen L, Yu Y, Zhou J, Lu H. Efficient production of porcine circovirus virus-like particles using the nonconventional yeast Kluyveromyces marxianus. Appl Microbiol Biotechnol 2019;103:833-42. [PMID: 30421111 DOI: 10.1007/s00253-018-9487-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
17 Fraiberk M, Hájková M, Krulová M, Kojzarová M, Drda Morávková A, Pšikal I, Forstová J. Exploitation of stable nanostructures based on the mouse polyomavirus for development of a recombinant vaccine against porcine circovirus 2. PLoS One 2017;12:e0184870. [PMID: 28922413 DOI: 10.1371/journal.pone.0184870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Chang XX, Fan K, Meng W, Guo J, Zhao D, Yin W, Li H, Wang Z. Truncated Diphtheria Toxin DT390 Enhances the Humoral Immunogenicity of Porcine Circovirus Type 2 Capsid Antigen in Mice. Viral Immunol 2021. [PMID: 33902339 DOI: 10.1089/vim.2020.0339] [Reference Citation Analysis]
19 Segalés J. Best practice and future challenges for vaccination against porcine circovirus type 2. Expert Review of Vaccines 2015;14:473-87. [DOI: 10.1586/14760584.2015.983084] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 7.9] [Reference Citation Analysis]
20 Silva JG, Coimbra EC, Jesus AL, Mariz FC, Silva KM, Lobato ZI, Campos AC, Coutinho LC, Castro RS, Freitas AC. Secretory expression of Porcine Circovirus Type 2 capsid protein in Pichia pastoris. Journal of Virological Methods 2014;207:226-31. [DOI: 10.1016/j.jviromet.2014.07.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
21 Li X, Meng X, Wang S, Li Z, Yang L, Tu L, Diao W, Yu C, Yu Y, Yan C, Wang L. Virus-like particles of recombinant PCV2b carrying FMDV-VP1 epitopes induce both anti-PCV and anti-FMDV antibody responses. Appl Microbiol Biotechnol 2018;102:10541-50. [PMID: 30338355 DOI: 10.1007/s00253-018-9361-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
22 Wei Z, Fu Q, Liu X, Chen Y. Attenuated Streptococcus equi ssp. zooepidemicus as a bacterial vector for expression of porcine circovirus type 2 capsid protein. FEMS Microbiol Lett 2012;332:20-6. [PMID: 22489773 DOI: 10.1111/j.1574-6968.2012.02569.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Wu PC, Chen TY, Chi JN, Chien MS, Huang C. Efficient expression and purification of porcine circovirus type 2 virus-like particles in Escherichia coli. J Biotechnol 2016;220:78-85. [PMID: 26795354 DOI: 10.1016/j.jbiotec.2016.01.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
24 Bal J, Luong NN, Park J, Song KD, Jang YS, Kim DH. Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate. Microb Cell Fact 2018;17:24. [PMID: 29452594 DOI: 10.1186/s12934-018-0876-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
25 Zepeda-Cervantes J, Cruz-Reséndiz A, Sampieri A, Carreón-Nápoles R, Sánchez-Betancourt JI, Vaca L. Incorporation of ORF2 from Porcine Circovirus Type 2(PCV2) into genetically encoded nanoparticles as a novel vaccine using a self-aggregating peptide. Vaccine 2019;37:1928-37. [PMID: 30824359 DOI: 10.1016/j.vaccine.2019.02.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Zaveckas M, Snipaitis S, Pesliakas H, Nainys J, Gedvilaite A. Purification of recombinant virus-like particles of porcine circovirus type 2 capsid protein using ion-exchange monolith chromatography. Journal of Chromatography B 2015;991:21-8. [DOI: 10.1016/j.jchromb.2015.04.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
27 Tamošiūnas PL, Petraitytė-Burneikienė R, Lasickienė R, Akatov A, Kundrotas G, Sereika V, Lelešius R, Žvirblienė A, Sasnauskas K. Generation of recombinant porcine parvovirus virus-like particles in Saccharomyces cerevisiae and development of virus-specific monoclonal antibodies. J Immunol Res 2014;2014:573531. [PMID: 25045718 DOI: 10.1155/2014/573531] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
28 Bazan SB, Geginat G, Breinig T, Schmitt MJ, Breinig F. Uptake of various yeast genera by antigen-presenting cells and influence of subcellular antigen localization on the activation of ovalbumin-specific CD8 T lymphocytes. Vaccine 2011;29:8165-73. [DOI: 10.1016/j.vaccine.2011.07.141] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
29 Yang S, Shang Y, Yin S, Tian H, Chen Y, Sun S, Jin Y, Liu X. Selection and identification of single-domain antibody fragment against capsid protein of porcine circovirus type 2 (PCV2) from C. bactrianus. Vet Immunol Immunopathol 2014;160:12-9. [PMID: 24736187 DOI: 10.1016/j.vetimm.2014.03.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
30 Wang Y, Wang G, Duan WT, Sun MX, Wang MH, Wang SH, Cai XH, Tu YB. Self-assembly into virus-like particles of the recombinant capsid protein of porcine circovirus type 3 and its application on antibodies detection. AMB Express 2020;10:3. [PMID: 31912330 DOI: 10.1186/s13568-019-0940-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Brahmania M, Feld J, Arif A, Janssen HL. New therapeutic agents for chronic hepatitis B. Lancet Infect Dis 2016;16:e10-21. [PMID: 26795693 DOI: 10.1016/S1473-3099(15)00436-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
32 Zhang C, Zhu S, Wei L, Yan X, Wang J, Quan R, She R, Hu F, Liu J. Recombinant Flagellin-Porcine Circovirus Type 2 Cap Fusion Protein Promotes Protective Immune Responses in Mice. PLoS One 2015;10:e0129617. [PMID: 26070075 DOI: 10.1371/journal.pone.0129617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
33 Masuda A, Lee JM, Miyata T, Sato T, Hayashi S, Hino M, Morokuma D, Karasaki N, Mon H, Kusakabe T. Purification and characterization of immunogenic recombinant virus-like particles of porcine circovirus type 2 expressed in silkworm pupae. J Gen Virol 2018;99:917-26. [PMID: 29851377 DOI: 10.1099/jgv.0.001087] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
34 Tao Y, Li G, Zheng W, Shu J, Chen J, Yang F, Wu Y, He Y. Development of a Combined Genetic Engineering Vaccine for Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae by a Baculovirus Expression System. Int J Mol Sci 2019;20:E4425. [PMID: 31505747 DOI: 10.3390/ijms20184425] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
35 Gunter CJ, Regnard GL, Rybicki EP, Hitzeroth II. Immunogenicity of plant-produced porcine circovirus-like particles in mice. Plant Biotechnol J 2019;17:1751-9. [PMID: 30791210 DOI: 10.1111/pbi.13097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
36 Yu C, Li X, Liu J, Diao W, Zhang L, Xiao Y, Wei H, Yu Y, Yu Y, Wang L. Replacing the decoy epitope of PCV2b capsid protein with a protective epitope enhances efficacy of PCV2b vaccine. Vaccine 2016;34:6358-66. [DOI: 10.1016/j.vaccine.2016.10.044] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
37 Zhu X, Liu J, Bai J, Liu P, Zhang T, Jiang P, Wang X. Baculovirus expression of the N-terminus of porcine heat shock protein Gp96 improves the immunogenicity of recombinant PCV2 capsid protein. J Virol Methods 2016;230:36-44. [PMID: 26826323 DOI: 10.1016/j.jviromet.2016.01.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
38 Yan D, Wei YQ, Guo HC, Sun SQ. The application of virus-like particles as vaccines and biological vehicles. Appl Microbiol Biotechnol 2015;99:10415-32. [PMID: 26454868 DOI: 10.1007/s00253-015-7000-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
39 Liu X, Liu Y, Zhang Y, Zhang F, Du E. Incorporation of a truncated form of flagellin (TFlg) into porcine circovirus type 2 virus-like particles enhances immune responses in mice. BMC Vet Res 2020;16:45. [PMID: 32028949 DOI: 10.1186/s12917-020-2253-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Bal J, Jung HY, Nguyen LN, Park J, Jang YS, Kim DH. Evaluation of cell-surface displayed synthetic consensus dengue EDIII cells as a potent oral vaccine candidate. Microb Cell Fact 2018;17:146. [PMID: 30217208 DOI: 10.1186/s12934-018-0994-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Aguilera BE, Chávez-Calvillo G, Elizondo-Quiroga D, Jimenez-García MN, Carrillo-Tripp M, Silva-Rosales L, Hernández-Gutiérrez R, Gutiérrez-Ortega A. Porcine circovirus type 2 protective epitope densely carried by chimeric papaya ringspot virus-like particles expressed in Escherichia coli as a cost-effective vaccine manufacture alternative. Biotechnol Appl Biochem 2017;64:406-14. [PMID: 26970530 DOI: 10.1002/bab.1491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
42 Hu G, Wang N, Yu W, Wang Z, Zou Y, Zhang Y, Wang A, Deng Z, Yang Y. Generation and immunogenicity of porcine circovirus type 2 chimeric virus-like particles displaying porcine reproductive and respiratory syndrome virus GP5 epitope B. Vaccine 2016;34:1896-903. [DOI: 10.1016/j.vaccine.2016.02.047] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
43 Zhang S, Mou C, Cao Y, Zhang E, Yang Q. Immune response in piglets orally immunized with recombinant Bacillus subtilis expressing the capsid protein of porcine circovirus type 2. Cell Commun Signal 2020;18:23. [PMID: 32046726 DOI: 10.1186/s12964-020-0514-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Wang N, Zhang Y, Lei X, Yu W, Zhan Y, Wang D, Zhang J, Wang A, Xiao L, Jiang P, Yang Y. Optimized conditions for preserving stability and integrity of porcine circovirus type2 virus-like particles during long-term storage. J Virol Methods 2017;243:146-50. [PMID: 28131868 DOI: 10.1016/j.jviromet.2017.01.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
45 Yang D, Chen L, Duan J, Yu Y, Zhou J, Lu H. Investigation of Kluyveromyces marxianus as a novel host for large-scale production of porcine parvovirus virus-like particles. Microb Cell Fact 2021;20:24. [PMID: 33494762 DOI: 10.1186/s12934-021-01514-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Zhu S, Zhang C, Wang J, Wei L, Quan R, Yang J, Yan X, Li Z, She R, Hu F, Liu J. Immunity Elicited by an Experimental Vaccine Based on Recombinant Flagellin-Porcine Circovirus Type 2 Cap Fusion Protein in Piglets. PLoS One 2016;11:e0147432. [PMID: 26848967 DOI: 10.1371/journal.pone.0147432] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
47 Chen F, Yang X, Pang D, Peng Z, Dong M, Liu X, Ouyang H, Ren L. Expression, purification and antibody preparation using different constructs of PCV2 capsid protein. Int J Biol Macromol 2014;67:289-94. [PMID: 24690536 DOI: 10.1016/j.ijbiomac.2014.03.043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
48 McKillen J, McNair I, Lagan P, McKay K, McClintock J, Casement V, Charreyre C, Allan G. Reproduction of post-weaning multi-systemic wasting syndrome in an animal disease model as a tool for vaccine testing under controlled conditions. Res Vet Sci 2016;105:143-52. [PMID: 27033924 DOI: 10.1016/j.rvsc.2016.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]